Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | TDO2 | P48775 | 2/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21938210 | 0.71 | IDO1 (0.38) | TRPA1IDO1ESR1 | |
| SCHEMBL20858119 | 0.71 | TRPV1 (0.35) | TRPA1IDO1 | |
| SCHEMBL17030759 | 0.69 | IDO1 (0.41) | TRPA1IDO1JAK2JAK1ESR1 | |
| SCHEMBL18408609 | 0.69 | — | — | |
| SCHEMBL24285781 | 0.67 | IDO1 (0.34) | TRPA1IDO1FGFR1ESR1 | |
| SCHEMBL24089313 | 0.67 | — | — | |
| SCHEMBL21024009 | 0.66 | AXL (0.34) | TRPA1 | |
| SCHEMBL24854355 | 0.66 | JAK2 (0.31) | JAK2 | |
| SCHEMBL20132851 | 0.66 | CYP2C9 (0.34) | ESR1 | |
| SCHEMBL21734001 | 0.65 | NOS1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10246424-B2 | Substituted quinazoline compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2019-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246424-B2 | Substituted quinazoline compounds and methods of use thereof | KRAS, NRAS, HRAS | HCAR2 3334/4885TRPA1 4572/4885IDO1 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.